Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Intravitreal AAVCAGsCD59 as Adjunct Anti-VEGF Treatment for Wet Age-Related Macular Degeneration
Jeffrey S. Heier, MD
Annual Meeting Talks
2020
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more